UBS Upgrades BioNTech to Buy, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Positive 83.4%

Neg 0% Neu 0% Pos 83.4%

UBS analyst David Dai upgrades BioNTech (NASDAQ:BNTX) from Neutral to Buy and raises the price target from $117 to $135.